Literature DB >> 22292814

Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification.

Fa Liu1, Jung-Eun Park, Wen-Jian Qian, Dan Lim, Andrej Scharow, Thorsten Berg, Michael B Yaffe, Kyung S Lee, Terrence R Burke.   

Abstract

In an effort to develop improved binding antagonists of the polo-like kinase 1 (Plk1) polo-box domain (PBD), we optimized interactions of the known high affinity 5-mer peptide PLHSpT using oxime-based post solid-phase peptide diversification of the N-terminal Pro residue. This allowed us to achieve up to two orders of magnitude potency enhancement. An X-ray crystal structure of the highest affinity analogue in complex with Plk1 PBD revealed new binding interactions in a hydrophobic channel that had been occluded in X-ray structures of the unliganded protein. This study represents an important example where amino acid modification by post solid-phase oxime ligation can facilitate the development of protein-protein interaction inhibitors by identifying new binding pockets that would not otherwise be accessible to coded amino acid residues.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22292814      PMCID: PMC3355227          DOI: 10.1021/cb200469a

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  19 in total

1.  Hydrolytic stability of hydrazones and oximes.

Authors:  Jeet Kalia; Ronald T Raines
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

2.  Elucidation of New Binding Interactions with the Tumor Susceptibility Gene 101 (Tsg101) Protein Using Modified HIV-1 Gag-p6 Derived Peptide Ligands.

Authors:  Sung-Eun Kim; Fa Liu; Young Jun Im; Andrew G Stephen; Matthew J Fivash; Abdul A Waheed; Eric O Freed; Robert J Fisher; James H Hurley; Terrence R Burke
Journal:  ACS Med Chem Lett       Date:  2011-05-12       Impact factor: 4.345

3.  Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation.

Authors:  Young H Kang; Jung-Eun Park; Li-Rong Yu; Nak-Kyun Soung; Sang-Moon Yun; Jeong K Bang; Yeon-Sun Seong; Hongtao Yu; Susan Garfield; Timothy D Veenstra; Kyung S Lee
Journal:  Mol Cell       Date:  2006-11-03       Impact factor: 17.970

4.  The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex.

Authors:  Kin-Yip Cheng; Edward D Lowe; John Sinclair; Erich A Nigg; Louise N Johnson
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

5.  Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.

Authors:  Sang-Moon Yun; Tinoush Moulaei; Dan Lim; Jeong K Bang; Jung-Eun Park; Shilpa R Shenoy; Fa Liu; Young H Kang; Chenzhong Liao; Nak-Kyun Soung; Sunhee Lee; Do-Young Yoon; Yoongho Lim; Dong-Hee Lee; Akira Otaka; Ettore Appella; James B McMahon; Marc C Nicklaus; Terrence R Burke; Michael B Yaffe; Alexander Wlodawer; Kyung S Lee
Journal:  Nat Struct Mol Biol       Date:  2009-07-13       Impact factor: 15.369

6.  Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk.

Authors:  K S Lee; T Z Grenfell; F R Yarm; R L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.

Authors:  Wolfgang Reindl; Juping Yuan; Andrea Krämer; Klaus Strebhardt; Thorsten Berg
Journal:  Chem Biol       Date:  2008-05

8.  Protected aminooxyprolines for expedited library synthesis: application to Tsg101-directed proline-oxime containing peptides.

Authors:  Fa Liu; Andrew G Stephen; Robert J Fisher; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2007-12-07       Impact factor: 2.823

9.  From crystal packing to molecular recognition: prediction and discovery of a binding site on the surface of polo-like kinase 1.

Authors:  Paweł Śledź; Christopher J Stubbs; Steffen Lang; Yong-Qing Yang; Grahame J McKenzie; Ashok R Venkitaraman; Marko Hyvönen; Chris Abell
Journal:  Angew Chem Int Ed Engl       Date:  2011-03-29       Impact factor: 15.336

10.  Promiscuous aggregate-based inhibitors promote enzyme unfolding.

Authors:  Kristin E D Coan; David A Maltby; Alma L Burlingame; Brian K Shoichet
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

View more
  31 in total

Review 1.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

2.  Design and synthesis of a reagent for solid-phase incorporation of the phosphothreonine mimetic (2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) into peptides in a bio-reversible phosphonyl-bis-pivaloyloxymethyl (POM) prodrug form.

Authors:  Wen-Jian Qian; Terrence R Burke
Journal:  Amino Acids       Date:  2013-08-02       Impact factor: 3.520

3.  Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs.

Authors:  Wen-Jian Qian; Jung-Eun Park; Dan Lim; Suk-Youl Park; Ki-Won Lee; Michael B Yaffe; Kyung S Lee; Terrence R Burke
Journal:  Chem Biol       Date:  2013-10-10

4.  Targeting Protein-Protein Interactions of Tyrosine Phosphatases with Microarrayed Fragment Libraries Displayed on Phosphopeptide Substrate Scaffolds.

Authors:  Megan Hogan; Medhanit Bahta; Kohei Tsuji; Trung X Nguyen; Scott Cherry; George T Lountos; Joseph E Tropea; Bryan M Zhao; Xue Zhi Zhao; David S Waugh; Terrence R Burke; Robert G Ulrich
Journal:  ACS Comb Sci       Date:  2019-01-31       Impact factor: 3.784

5.  Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.

Authors:  Xue Zhi Zhao; David Hymel; Terrence R Burke
Journal:  Bioorg Med Chem       Date:  2017-02-28       Impact factor: 3.641

6.  Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1.

Authors:  Ravichandran N Murugan; Jung-Eun Park; Dan Lim; Mija Ahn; Chaejoon Cheong; Taeho Kwon; Ky-Youb Nam; Sun Ho Choi; Bo Yeon Kim; Do-Young Yoon; Michael B Yaffe; Dae-Yeul Yu; Kyung S Lee; Jeong Kyu Bang
Journal:  Bioorg Med Chem       Date:  2013-02-27       Impact factor: 3.641

7.  Application of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain.

Authors:  Xue Zhi Zhao; David Hymel; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2016-09-02       Impact factor: 2.823

8.  Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.

Authors:  Campbell McInnes; Kara Estes; Merissa Baxter; Zhengguan Yang; Doaa Boshra Farag; Paul Johnston; John S Lazo; Jianjun Wang; Michael D Wyatt
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

9.  Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1).

Authors:  Wen-Jian Qian; Jung-Eun Park; Kyung S Lee; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2012-10-27       Impact factor: 2.823

10.  Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position.

Authors:  Wenjian Qian; Jung-Eun Park; Fa Liu; Kyung S Lee; Terrence R Burke
Journal:  Bioorg Med Chem       Date:  2012-05-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.